BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23272911)

  • 21. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
    Brenner AK; Andersson Tvedt TH; Bruserud Ø
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
    Pandurangan AK
    Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
    Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
    Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy.
    Ahmad A; Biersack B; Li Y; Kong D; Bao B; Schobert R; Padhye SB; Sarkar FH
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1002-13. PubMed ID: 23272910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
    Tan J; Yu Q
    Chin J Cancer; 2013 Jul; 32(7):376-9. PubMed ID: 23668928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S6K Promotes Dopaminergic Neuronal Differentiation Through PI3K/Akt/mTOR-Dependent Signaling Pathways in Human Neural Stem Cells.
    Lee JE; Lim MS; Park JH; Park CH; Koh HC
    Mol Neurobiol; 2016 Aug; 53(6):3771-3782. PubMed ID: 26143260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
    Blachly JS; Baiocchi RA
    Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
    Ramakrishnan V; Kumar S
    Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Sathe A; Nawroth R
    Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells.
    Puli S; Jain A; Lai JC; Bhushan A
    Neurochem Res; 2010 Jul; 35(7):986-93. PubMed ID: 20177775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXC195 induces apoptosis and endoplastic reticulum stress in human hepatocellular carcinoma cells by inhibiting the PI3K/Akt/mTOR signaling pathway.
    Chen XL; Fu JP; Shi J; Wan P; Cao H; Tang ZM
    Mol Med Rep; 2015 Dec; 12(6):8229-36. PubMed ID: 26496900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
    Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
    Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.